Clinical trials: Liver Malignant Tumors
Neuroendocrine Tumor, Liver Metastases
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options.
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- LUTARTERIAL (NCT04837885)
- Testing
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection
- Where
- 4 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Hepatocellular Carcinoma
Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma
¹¹C-choline positron emission tomography/computed tomography (PET/CT) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (HCC).
- Trial name
- NCT03430635
- Testing
- Hepatectomy
- Volunteers
- 40 people
- Sponsor
- Humanitas Clinical and Research Center
Hepatocellular Carcinoma Resectable
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition.
- Trial name
- NCT06294808
- Where
- 2 sites in Singapore
- Volunteers
- 1,043 people
- Sponsor
- National Cancer Centre, Singapore
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Hepatocellular Carcinoma
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.
- Trial name
- Shelter (NCT00943449)
- Testing
- 4SC-201, Sorafenib
- Where
- 15 sites in Germany, Italy
- Volunteers
- 57 people
- Sponsor
- 4SC AG
Gastric Cancer
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Background: Gastric (stomach) cancer is a rare cancer. In most cases, by the time it has been diagnosed it has spread to other organs in the body and the chance of a cure is very small.
- Trial name
- NCT00941655
- Testing
- Oxaliplatin, Irinotecan, 5-Fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Liver Carcinoma
A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer
The goal of this clinical trial is to investigate the BST02, a tumor infiltrating lymphocyte product, collected from the locally advanced liver cancer subjects The main questions it aims to answer are: 1.
- Trial name
- NCT06526832
- Testing
- BST02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- BioSyngen Pte Ltd
Hepatocellular Carcinoma, Liver Cirrhosis
Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis
Following the results of the randomized clinical trial IMbrave150, the combination of Atezolizumab with Bevacizumab became the first line regimen for patients with advanced hepatocellular carcinoma and it was approved by the FDA…
- Trial name
- SEEK (NCT07193316)
- Testing
- no intervention
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Metastases, Hepatocellular Carcinoma
Stereotactic Body Radiotherapy for Liver Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular…
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT01347333
- Testing
- Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mercy Research
Hepatocellular Carcinoma
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who…
- Trial name
- NCT06361758
- Testing
- Cadonilimab+Lenvatinib
- Where
- 3 sites in China
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC)
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
This is an early-phase study testing a new combination treatment for cancer. participants will receive a type of radiation therapy called MRI-guided or CT-guided radiotherapy, depending on which imaging method is safe for them.
- Trial name
- PRISM (NCT06994299)
- Testing
- Radiation Therapy, Tremelimumab, Durvalumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Hepatocellular Carcinoma
A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard
The study aims to evaluate the accuracy of ultrasound in diagnosing hepatocellular carcinoma (HCC), using histopathology as the gold standard.
- Trial name
- NCT06748755
- Testing
- Group 1
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Superior University
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Advanced Hepatocellular Carcinoma
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of…
- Trial name
- NCT04294498
- Testing
- Durvalumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
- Trial name
- TIKET (NCT06487663)
- Testing
- TACE with ICI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency
HCC (Hepato-cellular Carcinoma) is the fifth most frequent cancer in humans and its prevalence is growing. The most effective treatment of HCC is surgical and includes resection and liver transplantation; however, only 20% of the…
- Trial name
- HCC (NCT01322477)
- Testing
- F18-FDG PET/CT
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Hadassah Medical Organization
Gallbladder Cancer, Liver Cancer
Quality Of Life in Patients With Malignant Biliary Obstruction
You may have symptoms like itching, abdominal pain, loss of appetite, fatigue, fevers and chills. The treatment you will receive to relieve the blockage is also intended to relieve symptoms and improve your quality of life.
- Conditions
- Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT00579865
- Testing
- questionnaires
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Liver Cancer, Lung Cancer
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02239900
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Metastasis
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib for patients with unresectable liver metastasis, who had progressed after, or were refractory to first…
- Trial name
- NCT05098847
- Testing
- Sintilimab, Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.